参考文献/References:
[1]Rsch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. Radiology,1969,92(5):1112-1114.
[2]中华医学会消化病学分会消化介入学组.经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压共识意见.中华消化杂志,2014, 30(1):210-213.
[3]Lee EW, Kuei A, Saab S, et al. Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt. World J Gastroenterol,2016,22(25):5780-5789.
[4]Parvinian A, Shah KD, Couture PM, et al. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. J Vasc Interv Radiol,2013,24(7):941-946.
[5]Suraweera D, Jimenez M, Viramontes M, et al. Agerelated morbidity and mortality after transjugular intrahepatic portosystemic shunts. J Clin Gastroenterol,2017,51(4):360-363.
[6]Ascha M, Abuqayyas S, Hanouneh I, et al. Predictors of mortality after transjugular portosystemic shunt. World J Hepatol,2016,8(11):520-529.
[7]Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis. J Vasc Interv Radiol,2002,13(1):155-161.
[8]原姗姗, 韩国宏,柏明,等.TIPS治疗肝硬化顽固性腹水的预后因素分析.临床肝胆病杂志,2011,27(5):525-527.
[9]原姗姗, 韩国宏,柏明,等.经颈静脉肝内门体静脉分流术治疗肝硬化静脉曲张出血预后因素分析.中华消化杂志,2011,31(5):299-302.
[10]Bureau C, Métivier S, D’Amico M, et al. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol,2011,54(5):901-907.
[11]Taki Y, Kanazawa H, Narahara Y, et al. Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites. Hepatol Res,2014,44(8):871-877.
[12]Dhanasekaran R, Gonzales P, West J, et al. Predictors of early mortality post transjugular intrahepatic portosystemic shunts and the role of hepatic venous pressure gradient. Gastrointest Interv,2012,1(1):63-68.
[13]Angermayr B, Cejna M, Karnel F, et al. ChildPugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut,2003,52(6):879-885.
[14]Basset L, Chevalier S, Danger Y, et al. Interleukin27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. J Mol Med,2015,93(12):1355-1367.
[15]Berres M, Asmacher S, Lehmann J, et al. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol,2015,62(2):332-339.
[16]丁远,王黎洲,黄学卿，等.乙肝肝硬化门静脉高压患者TIPS前后门静脉、肝静脉血清CXCL9水平变化及其意义.山东医药,2017,57 (8):70-72.
[17]Berres ML, Lehmann J, Jansen C, et al. Chemokine(CXC motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int,2016,36(3):386-394.
[18]Parvinian A, Minocha J, Knuttinen M, et al. Right atrial pressure impacts early survival of patients undergoing transjugular intrahepatic portosystemic shunt creation. Ann Hepatol,2014,13(4):411-419.
[19]Vasatova M, Pudil R, Safka V, et al. Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Ann Clin Biochem,2013,50(2):122-126.
[20]徐征国,赵泳冰,郑媛钰,等.肝硬化患者经颈静脉肝内门体分流术后门静脉压力下降梯度与预后的关系.临床肝胆病杂志,2016, 32(12): 2326-2330.
[21]Ruizblard E, Baiges A, Turon F, et al. Early transjugular intrahepatic portosystemic shunt: When, how and in whom? Gastroenterol Hepatol,2016,39(7):472-476.
[22]Franchis RD. Expanding consensus in portal hypertension : report of the Baveno Ⅵ consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63(3):743-752.
[23]Halabi SA, Sawas T, Sadat B, et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a metaanalysis of randomized controlled trials. J Gastroenterol Hepatol,2016,31(9):1519-1526.
[24]Njei B, Mccarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroentero Hepatol,2017,32(4):852-858.
[25]Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo Endstage Liver Disease. Hepatology,2001,33(2):473-475.
[26]巨伟, 张博静,韩国宏.经颈静脉肝内门体分流术治疗肝硬化顽固性腹水的长期效果及预后因素分析.临床肝胆病杂志,2016,32(8):1529-1533.
[27]Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology,2000,31(4):864-871.
[28]Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with endstage liver disease. Hepatology,2001,33(2):464-470.
[29]Zhang F, Zhuge Y, Zou X, et al. Different scoring systems in predicting survival in Chinese patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol,2014,26(8):853-860.
[30]Biggins SW, Kim WR, Terrault NA, et al. Evidencebased incorporation of serum sodium concentration into MELD. Gastroenterol,2006,130(6):1652-1660.
[31]Ahmed R, Santhanam P, Rayyan Y. MELDNa as a prognostic indicator of 30 and 90day mortality in patients with endstage liver disease after creation of transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol,2015,27(10): 1226-1227.
[32]Guy J, Ma S, Shiboski S, et al. A new model for endstage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol,2009,7(11):1236-1240.
[33]Huo TI, Wang YW, Yang YY, et al. Model for endstage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int,2007,27(4):498-506.
[34]Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl,2007,13(8):1174-1180.
[35]文龙跃, 何松, 张浩,等.五种评分系统对经颈静脉肝内门体静脉分流术患者预后的评价比较.中华肝脏病杂志,2014, 22(7):514-518.
[36]Gaba RC, Couture PM, Bui JT, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol,2013,24(3):411-420.
[37]Grunwald D, Tapper EB, Jiang ZG, et al. A standardized assessment of functional disability predicts 1year mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) for refractory ascites. J Clin Gastroenterol,2016,50(1):75-79.
[38]Ronald J, Wang Q, Suhocki P, et al. Comparison of albuminbilirubin grade and Model for EndStage Liver Disease score for predicting survival after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol,2017,28(2):S231-S232.
[39]孙亚朦,尤红.乙型肝炎肝硬化的分期及治疗进展.临床肝胆病杂志,2016,32（6）：1036-1039.
[40]Okada M, Enomoto M, Kawada N, et al. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol,2017,8(7):1-10.
[41]林静, 魏波, 吴浩,等.抗病毒治疗对失代偿期乙型肝炎肝硬化患者经颈静脉肝内门体分流术预后的影响.临床肝胆病杂志,2016,32(2):254-258.
[42]李松蔚, 张捷, 李迎春.经颈静脉肝内门体静脉分流术治疗肝硬化门静脉高压症的研究进展.中国微创外科杂志,2014,14(9):844-848.
[43]胡朋,陈斯良,罗泽龙等.采用裸支架联合覆膜支架建立经颈静脉肝内门体分流术的中远期疗效.中国介入影像与治疗学,2016,13(7):394-397.